New agents improve survival time at high cost in metastatic colorectal cancer patients
HemOnc today
Posted May 6, 2010
New chemotherapeutic agents used to treat metastatic colorectal cancer were shown to have high costs associated with their survival benefits, although the costs fell below common estimates of willingness-to-pay amounts for a life-year.
Between 1996 and 2004, several chemotherapy agents were approved to treat patients with metastatic...
Daily Mail Online
By Jenny Hope
Last updated at 8:55 AM on 6th May 2010
Thousands of cancer sufferers are set to be denied a 'miracle' drug on the NHS that is routinely used in virtually every other Western country.
The Government's rationing body says Avastin is not cost-effective despite evidence that it can prolong the lives of bowel cancer patients by more than two years.
The final decision is due next month, but NICE, the National Institute...
Avastin, the cancer drug made by Roche, is set to become the world’s bestselling medicine in the next four years as patents expire on the mighty Lipitor, the cholesterol-lowering medicine made by Pfizer.
Roche’s triumph proves that it is still possible to produce a genuine blockbuster drug if you come up with something novel for a life-threatening condition. Governments and insurers will still pay out for a medicine that is first in its...
ROCKVILLE, Md., April 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health...
